Niagen Bioscience Strengthens R&D Leadership with Kale Appointment — Niagen Bioscience, Inc.

Event summary

Niagen Bioscience appoints Abhijit Kale, Ph.D., as Senior Director of Global External Research effective July 20, 2026.
Dr. Kale brings over a decade of experience in aging biology and scientific partnerships from roles at Hevolution Foundation, Buck Institute for Research on Aging, Deciduous Therapeutics, and LevitasBio.
The Niagen Research Program supports 175 ongoing studies, with 45+ peer-reviewed clinical studies published on Niagen to date.
Under Dr. Kale's leadership, the company plans to expand research into pharmaceutical-grade NAD+ injections, topical applications, and novel NAD+ precursors.

The big picture

Niagen Bioscience's appointment of Dr. Kale underscores its commitment to advancing NAD+ science through strategic external research partnerships. The move aligns with the broader industry trend of leveraging academic collaborations to drive innovation in healthy aging. With over 175 ongoing studies and a robust patent portfolio, Niagen Bioscience is positioning itself as a key player in the healthspan field.

What we're watching

Research Expansion: How the expansion into pharmaceutical-grade NAD+ injections and topical applications will impact Niagen Bioscience's market position.
Scientific Leadership: Whether Dr. Kale's extensive experience in aging biology and scientific partnerships can accelerate breakthroughs in NAD+ research.
Collaborative Growth: The pace at which Niagen Bioscience can deepen collaborations with leading academic and clinical research institutions globally.